Clinical Trials Directory

Trials / Unknown

UnknownNCT04822532

Precision Dosing of Busulfan in Children Undergoing HSCT

Implementing Pharmacogenetics in the Busulfan Dosing Method for Children Undergoing Hematopoietic Stem-cell Transplantation: a Prospective, Multicentric, Randomized Clinical Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
260 (estimated)
Sponsor
University Hospital, Geneva · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of this clinical trial is to evaluate the personalization the conditioning regimen prior to the hematopoietic stem cell transplant (HSCT) in children and adolescents, to improve HSCT efficacy while reducing conditioning-related toxicities. Namely, we are going to compare the accuracy of two methods for determining the first dose of busulfan, one of the medicines used during the conditioning regimen. First doses will be determined based either only on anthropometric information such as age and weight or by adding a genetic factor that influences the individual ability of busulfan metabolization.

Detailed description

Participants will be randomly assigned (1:1 ratio, stratified by conditioning regimen - the presence of fludarabine) to receive their first dose of busulfan according to: 1. the most performing method based on age and weight - McCune's model (control arm) 2. a method that also considers a pharmacogenetic factor (variants occurring in the promoter region of the GSTA1 gene) in association with the co-administered chemotherapeutic agent fludarabine in the dose personalization (experimental arm) This is an international study being carried out in five countries (Canada, Italy, Switzerland, France, and Denmark).

Conditions

Interventions

TypeNameDescription
GENETICGSTA1 genotypingDiplotype determination based on 4 single-nucleotide polymorphisms (SNPs) occurring in the promoter region of the GSTA1 gene

Timeline

Start date
2021-06-15
Primary completion
2025-06-01
Completion
2025-06-01
First posted
2021-03-30
Last updated
2021-08-02

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT04822532. Inclusion in this directory is not an endorsement.